{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022959","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.786696+00:00","generated_at":"2026-06-13T14:36:54.274736+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Elite Pharma FY2023 revenue $34.2M (+5.9% YoY); operating profit down $1.4M","bullets":["FY2023 revenues $34.2M, up 5.9% from prior year; net income $3.6M.","Operating profit $3.7M, a decrease of $1.4M due to higher R&D and sales-distribution investment.","Company will host conference call June 30 at 11:30 AM EDT to discuss results.","Stockholder questions accepted via email prior to the call."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022959","json":"https://secwatch.observer/filing/0001493152-23-022959.json","markdown":"https://secwatch.observer/filing/0001493152-23-022959.md","text":"https://secwatch.observer/filing/0001493152-23-022959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/0001493152-23-022959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:36:54.274736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2a6dea056109bcb063511bf1dc1ce34dd9f2d10","claim":"ELITE PHARMACEUTICALS INC /NV/ reported the fiscal year ended March 31, 2023 results: revenue $34.2 million, net income $3.6 million.","evidence_excerpt":"Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year. Operating profits were $3.7 million, a decrease of $1.4 million from the comparable period of the prior year, and net income was $3.6 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/0001493152-23-022959-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended March 31, 2023"},{"label":"Revenue","value":"$34.2 million"},{"label":"Net income","value":"$3.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}